ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,918.25
0.00%
Dow Jones
42,635.20
0.00%
US Dollar vs MXN
20.5152
0.02%
Brent Oil
79.32
3.11%
Bitcoin
94,825.34
2.61%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Precision BioSciences Inc (DTIL) Cotización

Precision BioSciences Inc

Precision BioSciences Inc (DTIL)

NASDAQ
4.50
-0.29
(-6.05%)
Cerrado 08 Enero 3:00PM
Delayed by 15 minutes
7.50
3.00
( 66.67% )
Pre Mercado: 6:56AM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
7.50
Postura de Compra
7.49
Postura de Venta
7.51
Volume Operado de la Acción
1,843,353
0.00 Rango del Día 0.00
3.61 Rango de 52 semanas 19.4299
Capitalización de Mercado [m]
57.533M
Precio Anterior
4.50
Precio de Apertura
-
Hora
5
@
7.5
Última hora de negociación
06:56:08
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
132,167
Acciones en circulación
7,671,059
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.56
Beneficio por acción (BPA)
-7.99
turnover
48.73M
Beneficio neto
-61.32M

Acerca de Precision BioSciences Inc

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segment... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.precisionbiosciences.com
Sede
Wilmington, Delaware, USA
Fundado
-
Precision BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DTIL. The last closing price for Precision BioSciences was US$4.50. Over the last year, Precision BioSciences shares have traded in a share price range of US$ 3.61 to US$ 19.4299.

Precision BioSciences currently has 7,671,059 shares in issue. The market capitalisation of Precision BioSciences is US$34.52 million. Precision BioSciences has a price to earnings ratio (PE ratio) of -0.56.

DTIL Últimas noticias

Más noticias

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no...

22 horas hace
Business Wire

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 1013 GC/kg) of ECUR-506 from three months...

09 Enero 2025
Business Wire

Form 8-K - Current report

08 Enero 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

02 Enero 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

31 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

31 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

30 Diciembre 2024
Edgar (US Regulatory)

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in...

18 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

21 Noviembre 2024
Edgar (US Regulatory)

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene...

21 Noviembre 2024
Business Wire
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
12.6454.32098765434.868.074.51324464.70116498CS
41.42523.45679012356.0758.073.612130364.52010355CS
12-1.4-15.73033707878.99.23.611321676.05478768CS
26-1.65-18.03278688529.1511.093.61827127.07521699CS
52-6-44.444444444413.519.42993.6119438010.96910855CS
156-187.5-96.15384615381952013.6183095638.00160275CS
260-437.7-98.3153638814445.24983.61763406122.75080073CS

DTIL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Precision BioSciences?
El precio actual de las acciones de Precision BioSciences es US$ 7.50
¿Cuántas acciones de Precision BioSciences están en circulación?
Precision BioSciences tiene 7,671,059 acciones en circulación
¿Cuál es la capitalización de mercado de Precision BioSciences?
La capitalización de mercado de Precision BioSciences es USD 34.52M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Precision BioSciences?
Precision BioSciences ha negociado en un rango de US$ 3.61 a US$ 19.4299 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Precision BioSciences?
El ratio precio/beneficio de Precision BioSciences es -0.56
¿Cuál es el ratio de efectivo a ventas de Precision BioSciences?
El ratio de efectivo a ventas de Precision BioSciences es 0.71
¿Cuál es la moneda de reporte de Precision BioSciences?
Precision BioSciences presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Precision BioSciences?
El último ingresos anual de Precision BioSciences es USD 48.73M
¿Cuál es el último beneficio anual de Precision BioSciences?
El último beneficio anual de Precision BioSciences es USD -61.32M
¿Cuál es la dirección registrada de Precision BioSciences?
La dirección registrada de Precision BioSciences es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Precision BioSciences?
La dirección del sitio web de Precision BioSciences es www.precisionbiosciences.com
¿En qué sector industrial opera Precision BioSciences?
Precision BioSciences opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
JSPRWJasper Therapeutics Inc
US$ 0.3074
(98.32%)
2
VMARVision Marine Technologies Inc
US$ 2.59
(70.39%)
24.24M
DTILPrecision BioSciences Inc
US$ 7.46
(65.78%)
1.65M
BAERBridger Aerospace Group Holdings Inc
US$ 4.02
(44.09%)
11.65M
MVSTMicrovast Holdings Inc
US$ 2.51
(34.22%)
7.56M
IGMSIGM Biosciences Inc
US$ 2.17
(-65.00%)
340.55k
XXII22nd Century Group Inc
US$ 5.69
(-29.75%)
10.02k
AVDLAvadel Pharmaceuticals PLC
US$ 7.96
(-25.54%)
54.28k
WMPNWilliam Penn Bancorporation
US$ 9.01
(-22.99%)
1
FBLAFB Bancorp Inc
US$ 9.01
(-21.38%)
1
VMARVision Marine Technologies Inc
US$ 2.59
(70.39%)
24.24M
IINNInspira Technologies Oxy B H N Ltd
US$ 1.04
(4.00%)
18.78M
ZVSAZyVersa Therapeutics Inc
US$ 1.52
(28.81%)
18.17M
FAMIFarmmi Inc
US$ 0.332
(1.78%)
15.83M
GCTKGlucoTrack Inc
US$ 0.135
(-2.74%)
14.36M

DTIL Discussion

Ver más
tw0122 tw0122 11 minutos hace
Gene editing news $5 to $7s next 
👍️0
Monksdream Monksdream 3 semanas hace
DTIL under $5
👍️0
Monksdream Monksdream 4 meses hace
DTIL under $10
👍️0
Monksdream Monksdream 6 meses hace
DTIL under $10
👍️0
jondoeuk jondoeuk 7 meses hace
I think they did, but there are still a lot of vampires sucking away at the (limited) revenue.
👍️0
Monksdream Monksdream 8 meses hace
DTIL under $10
👍️0
NY1972 NY1972 9 meses hace
Why they hired a Chief People Officer instead of of trimming head count? another GNCA IMO
👍️0
jondoeuk jondoeuk 9 meses hace
Management can try and spin this as much as they want, but this is a failure https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics
👍️0
jondoeuk jondoeuk 9 meses hace
If one of the companies that are developing off-the-shelf succeed, I don't see why any insurer will pay the price tag of an autologous therapy (assuming similar data/success). On paper, it should be easier than oncology.
👍️0
Monksdream Monksdream 10 meses hace
DTIL 10Q due March 13
👍️0
jondoeuk jondoeuk 10 meses hace
That didn't take long! https://www.businesswire.com/news/home/20240301968620/en/Precision-BioSciences-Announces-40.0-Million-Offering-of-Common-Stock-and-Warrants

Maybe things are going slower on the clinical front or no milestone payments are expected.
👍️0
rtrstock rtrstock 11 meses hace
What do you mean an offering?
👍️0
surf1944 surf1944 11 meses hace
Precision BioSciences, Inc. (DTIL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, February 14, 2024. In conjunction with the reverse split, the CUSIP number will change to 74019P207

The 1 for 30 R/S will make it easy is come out with an offering in the next week or so.
👍️0
rtrstock rtrstock 11 meses hace
1 for 30 not bad, but still will have to hold a long time to get my money back, if I ever do, averaged in at maybe 1.30, so uncertain what price will need to be after reverse split eventually to even break even. Wanting to hold long and make money eventually, but unsure if that's still possible.

I have 5100 shares, so that will be cut to practically nothing, it'd have to go to nearly 50.00 a share for me to make my money back?

Is this correct? Is basically everyone even the big investors like Lilly and Cargill losing big on this one?
👍️0
jondoeuk jondoeuk 11 meses hace
Now there will be one. The BOD approved a 1-for-30 R/S. It will become effective at 5:00 p.m. ET on Feb 13. The uncertainty has been eliminated.
👍️0
rtrstock rtrstock 11 meses hace
Guess I'll hold even if there is a R/S
👍️0
jondoeuk jondoeuk 12 meses hace
I thought they would, but it seems to me that they want to allow the clock to run before they set a R/S. Looking at the filing, it leaves the effective date to the BOD's discretion. It also gives the them the discretion to abandon it. The company has until the 22nd of April for the stock price to attain what is needed, thereby keeping its listing.
👍️0
NY1972 NY1972 12 meses hace
Side dish becomes the main course. High paid bio CEOs need another bait and switch.
👍️0
jondoeuk jondoeuk 12 meses hace
Autoimmune diseases are clearly the next frontier for CAR-T/NK cell therapies, with numerous biotech and (big) pharma companies in the space https://finance.yahoo.com/news/precision-biosciences-completes-license-deal-120000510.html
👍️ 1
81vette 81vette 1 año hace
Res. Breakout,after hours could get fun
👍️ 1
81vette 81vette 1 año hace
Accumulation at nhod
👍️ 1
81vette 81vette 1 año hace
11th most newly watched ticker,do dd,others are
👍️0
81vette 81vette 1 año hace
The 2.5m buy, should open some eyes
👍️0
81vette 81vette 1 año hace
Death hour is over,mid day vol surge coming,this pennant has gotten pointy/pokey/stabby(technical terms lol)held strong with .4333 last low bounce,demand growing now,waiting for thru .44 to send it higher
👍️0
81vette 81vette 1 año hace
DTIL astronomical potential=greed/hold,tutes own 27%,insiders 21%,100M cash(no offerings),eps this year up 60%/sales past 5years up 102%(tells me sales have started and that explains tutes,I expect they buy more now) 27%below the sma200(so it’s got at least that much run room) target price 2.62, 198 employees,bullish chart since Oct 30th,could be some bashers because it is optionable/shortable,institutional could send this flying up,relative buying vol up 148Xs today ,shares available to short is dropping but still 3.5M(was 4.3m) overall I like that I can put this in my portfolio for long(or until chart breaks) and not have to watch it like a nail biting pump and dump,I have too many of those already lol
👍️0
rtrstock rtrstock 1 año hace
What indication of a RS is there? Or is it assumed?

This looks like a good buy to me, am I wrong?
👍️0
NY1972 NY1972 1 año hace
Plenty dead bios walking in this mkt. still handing out options like clock work.
👍️0
NY1972 NY1972 1 año hace
This bio is walking dead. Failure to let go the PhDs and CARTs a few years ago costed hundreds millions. ARCUS will be bought by IECure after the cash dries up.
👍️0
jondoeuk jondoeuk 1 año hace
Yes, but I think the R/S will happen.
👍️0
Sirpeter Sirpeter 1 año hace
There's still time
👍️0
jondoeuk jondoeuk 1 año hace
So, at 4:30pm the day before Thanksgiving, they announce a special meeting to vote on a R/S. It will take place on Thurs, Jan 18, '24, at 11:00 am, Eastern Time, at a ratio ranging from 1-for-10 and 1-for-30.
👍️0
Sirpeter Sirpeter 1 año hace
Moving up nicely...looks good
👍️0
knrorrel knrorrel 1 año hace
nice chart, bottom now and here, Now get the news out and let's see what happens, maybe we'll almost never see these low prices down here on the ground again.
imho
👍️0
knrorrel knrorrel 1 año hace
News Out, should running hard in good News
imho
👍️0
knrorrel knrorrel 1 año hace
a really nice $DTIL News https://ih.advfn.com/stock-market/NASDAQ/precision-biosciences-DTIL/stock-news/92484281/precision-biosciences-reports-third-quarter-2023-f


👍️0
rtrstock rtrstock 1 año hace
Well on stock twits they are saying there is no filed reverse split and that they are expecting an extension to be filed, so I hope you are right. I'm uncertain what all is going on, but I like what this company is doing with it's aspirations in medicine, so staying with it. Just accumulated more, lowered my average cost.
👍️0
konshe konshe 1 año hace
bottom rebound coming, time to buy.
👍️ 1
Monksdream Monksdream 1 año hace
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DTIL new 52 wewek low
👍️0
NY1972 NY1972 1 año hace
DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim the expenses to make sure there will be cash left for clinical trials. High burn and lots of GT bios spell doom for this bio.
👍️0
jondoeuk jondoeuk 1 año hace
I should have pointed out that companies are happening to develop small[er] nucleases. Here is one paper from Casebia Therapeutics, which is a joint venture between CRSP and BAYN https://www.nature.com/articles/s41467-021-24454-5

Also, in 2020, researchers led by Dr. Liu created a new base editor that could perform C-to-T conversion of DNA in mitochondria. However, it had limitations, not only being restricted to that conversion, but mostly limited a certain motif. This means that it could correct only 10% of confirmed pathogenic mitochondrial point mutations https://www.nature.com/articles/s41587-022-01256-8

Last year another novel base editor was created that could achieve A-to-G conversion. Being able to perform that could correct 43% of confirmed pathogenic mitochondrial point mutations https://www.cell.com/cell/fulltext/S0092-8674(22)00389-0

However, I don't see either base editor entering the clinic for a number of years.
👍️0
jondoeuk jondoeuk 1 año hace
Or it could end up like TRIL. ARCUS has some benefits over current CRISPR systems, manly its size, can edit the mitochondrial genome and IP is not a mess.
👍️0
NY1972 NY1972 1 año hace
IECure will buy the ARCUS IP when cash is 0 in 18 months.
👍️0
jondoeuk jondoeuk 1 año hace
Not the most productive use of its cash so far. The R&D Day could change that, but the market doesn't seem to think it.
👍️0
NY1972 NY1972 1 año hace
this is a homeless shelter for PhDs. Cash is not spent on patients. They hired a chief people officer to cut the pie.
👍️0
jondoeuk jondoeuk 1 año hace
The market did not find the recent announcement attractive https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer

I think a reverse split is a possibility, especially after the announcement couldn't move the PPS. If that happens, will likely add fuel to any downward price pressure. Management don't seem the best. Now it's do or die with the in vivo programs.
👍️0
rtrstock rtrstock 1 año hace
That's what I'm afraid of, guess I'll just wait. Keep my shares.
👍️0
J-mak J-mak 1 año hace
In my opinon slim very very slim
👍️0
rtrstock rtrstock 1 año hace
What's the educated guess?

What's realistically possible by October date for pps to be more than $1.00
👍️0

Su Consulta Reciente

NASDAQ
DTIL
Precision BioSciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados